Taro Pharmaceutical Industries Overview
Valuation check: TARO's P/E ratio is 30.05, above the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow30.05
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Taro Pharmaceutical Industries's p/e ratio stands at 30.05. That is above the Healthcare sector average of 25.3. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Taro Pharmaceutical Industries sits higher the Healthcare benchmark (25.3) with a P/E ratio of 30.05. That is roughly 18.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether 30.05 is attractive depends on Taro Pharmaceutical Industries's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Taro Pharmaceutical Industries's P/E ratio evolved across reporting periods, while the comparison chart places TARO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Taro Pharmaceutical Industries's reading of 30.05 (sector avg 25.3) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
